Comparative Pharmacology
Head-to-head clinical analysis: MEFENAMIC ACID versus TOLECTIN DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEFENAMIC ACID versus TOLECTIN DS.
MEFENAMIC ACID vs TOLECTIN DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibition of cyclooxygenase (COX-1 and COX-2) leading to decreased prostaglandin synthesis; exhibits both central and peripheral analgesic effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
500 mg orally as an initial dose, followed by 250 mg every 6 hours as needed, not to exceed 1 week.
400 mg orally three times daily; maximum dose 1800 mg/day.
None Documented
None Documented
Terminal half-life is 2-4 hours; prolonged in hepatic impairment and overdose.
Clinical Note
moderateMefenamic acid + Gatifloxacin
"Mefenamic acid may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateMefenamic acid + Rosoxacin
"Mefenamic acid may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateMefenamic acid + Levofloxacin
"Mefenamic acid may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateMefenamic acid + Trovafloxacin
Terminal elimination half-life approximately 1 hour; clinical context: requires frequent dosing every 6-8 hours due to short half-life.
Primarily renal (52% as glucuronide metabolites, <6% unchanged) and fecal (20-30% via biliary elimination).
Primarily renal, 95% of a dose excreted in urine as glucuronide conjugates and oxidative metabolites; less than 5% fecal.
Category D/X
Category C
NSAID
NSAID
"Mefenamic acid may increase the neuroexcitatory activities of Trovafloxacin."